ADRIAMYCIN PLUS ZINECARD V NO TREATMENT IN ADVANCED BREAST CA AFTER 6 CYCLES CAF

这项随机的IIIb期2期武装试验的主要目标是 1)评估阿霉素和右氧氟沙星是否继续治疗 (这是心脏保护的)延长了患者的进展时间 病情稳定或有反应的局部晚期或转移性乳腺癌 在接受了六个疗程的一线CAF化疗后， 化疗在6个疗程后中断的相似患者 2)这些药物的持续治疗是否延长 疾病进展、发生心力衰竭或死亡的时间与 化疗间歇期患者；3)评价治疗效果 两种药物的性能状况、肿瘤相关症状和安全性。

The primary objectives of this randomized Phase IIIb two armed trial are to 1) evaluate whether continuing therapy with Adriamycin and dexrazoxane (which is cardioprotective) prolongs time to progression in patients with locally advanced or metastatic breast cancer who are stable or in response after receiving six courses of front-line CAF chemotherapy compared to similar patients whose chemotherapy has been interrupted after 6 courses of chemotherapy; 2) whether continuing therapy with these agents prolongs time to disease progression, development of CHF, or death compared to patients who had chemotherapy interrrupted; 3) to evaluate the effect on performance status, tumor-related symptoms and safety of both agents.